Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05729516
Other study ID # 2022/06/30
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 2024
Est. completion date August 2024

Study information

Verified date January 2024
Source See Yourself Health LLC
Contact Suzanne Mitchell, MD, MS
Phone 570-324-4928
Email smitchell@seeyourselfhealth.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study will test how a computer program (called the Hope App) teaches diabetes care skills for older adults with diabetes. The study will compare those who receive diabetes education (10 educational modules and monthly health coaching) through the research program with those who receive care as usual.


Description:

The Hope App offers a simple, high-impact, engaging, and immersive telehealth experience with the potential to become a ubiquitous diabetes management tool to transform diabetes patients into high performing drivers of their own care. The research team aims to scale the platform, develop features that are important to aging adults, and run a clinical trial to validate the Hope App's health benefits. - Specific Aim 1: Develop the Hope App's state-of-the-art immersive patient engagement experience with automated onboarding, social networking and gamified DSME/S features to support long-term patient retention. In doing so, usability testing will be performed to ensure patient-facing features on the platform and patient-facing content and curriculum materials are functioning and well received by participants. - Specific Aim 2: Develop the Hope App's predictive analytic capabilities for population health management. - Specific Aim 3: Conduct a clinical validation trial of the Hope App intervention on six-month clinical outcomes (Hemoglobin A1c), patient reported outcomes (diabetes distress) and engagement outcomes (patient retention, adherence to self-care behaviors). The research team intends to deliver a scalable Hope App platform with a usable patient engagement portal designed for older adults and achieve decreases in blood glucose levels (HbA1c) and depressive burden, and sustained patient engagement.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date August 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - aged 65 years and above - diagnosis of type 2 diabetes - English-speaking - baseline blood sugar value (HbA1c) of 7.5% - Internet access Exclusion Criteria: - aged less than 65 years - non English-speaking - unable to provide informed consent - diagnosis of type 1 diabetes - unable to use a computer or mobile device - medical condition for which participation is contraindicated (dialysis, pregnancy, use of insulin pump)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Hope App immersive learning and telehealth platform
As part of the Hope App intervention, participants attend 10 skills sessions related to diabetes self-management. ITG participants will also receive monthly health coaching calls. After 6 months of active participation, participants enter a maintenance period, during which programming concludes but continued access to the program materials remains.

Locations

Country Name City State
United States University of Louisville Louisville Kentucky

Sponsors (2)

Lead Sponsor Collaborator
See Yourself Health LLC University of Louisville

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary change in glycemic control change in HbA1c values recorded from point-of-care tests or in the electronic health record at visits.
A mean change of 0.5% will be the a priori determined clinically meaningful minimum improvement from baseline to 6 months.
baseline and 6 months
Secondary changes in self-reported diabetes distress self-reported changes in diabetes distress scale baseline to 3 months; 3 months to 6 months; baseline to 6 months
Secondary self-reported weight change self-reported weight change in pounds baseline to 3 months; 3 months to 6 months; baseline to 6 months
Secondary changes in participant engagement proportion of utilization metrics met (frequency of use, feature interactions) baseline to 3 months; 3 months to 6 months; baseline to 6 months
Secondary changes in self-management adherence self-reported changes in the 11-item Summary of Diabetes Self-Care Activities Assessment. The first 10 items are summed to a total score and averaged to 5 scale scores; the scales are General Diet, Specific Diet, Exercise, Blood-Glucose Testing, and Foot Care. Mean number of days will be assessed for self-management behaviors. The 11th question assess smoking status (yes(1), no(0)). baseline to 3 months; 3 months to 6 months; baseline to 6 months
Secondary changes in medication adherence scale self-reported changes in the Morisky Medication Adherence scale. There are 4-item and 8-item versions with higher scores indicating higher levels of adherence to medication. baseline to 3 months; 3 months to 6 months; baseline to 6 months
Secondary changes in depressive burden symptoms self-reported changes in Patient Health Questionnaire (PHQ)-9. PHQ-9 total score over nine items ranges from 0-24, with higher scores indicative of greater depressive symptom burden. baseline to 3 months; 3 months to 6 months; baseline to 6 months
Secondary changes in general anxiety symptoms self-reported changes in General Anxiety Disorder (GAD)-7 questionnaire. GAD-7 total score over seven items ranges from 0-21, with higher scores indicative of increased symptoms of anxiety. baseline to 3 months; 3 months to 6 months; baseline to 6 months
Secondary changes in coping skills self-reported changes to Brief Resilient Coping Scale. The total score over 4 items ranges from 4-20, with higher scores indicative of high resilient coping. baseline to 3 months; 3 months to 6 months; baseline to 6 months
Secondary changes in perceived support from healthcare providers self-reported changes in Healthcare Climate Questionnaire baseline to 3 months; 3 months to 6 months; baseline to 6 months
Secondary changes in perceived competence self-reported changes in Perceived Competence in Diabetes Scale. There are 4-items on a Likert scale from 1-7 with higher scores representing a higher degree to which people with diabetes feel they can self-manage their diabetes. The mean score is used as a summary score. baseline to 3 months; 3 months to 6 months; baseline to 6 months
Secondary changes in perceived diabetes self-efficacy self-reported changes in diabetes self-efficacy scale. There are 8 items on a Likert scale from 1 to 10. The score for the scale is the mean of the eight items. Higher number is indicative of higher self-efficacy. baseline to 3 months; 3 months to 6 months; baseline to 6 months
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A